Office of Research Integrity
IBC Submission Process for Human Research applications
All human gene transfer clinical trials occurring at or sponsored by institutions receiving NIH funds for recombinant DNA research must be submitted to the NIH Office of Biotechnology Activities (OBA) for review by the Recombinant DNA Advisory Committee (RAC). If MUSC is added as a site in a multi-center trial, RAC review occurs before final IBC approval in order to inform that committee of the RAC's recommendations before the IBC makes its final determination.
If MUSC is initiating a gene transfer trial, information can be found about protocol submission deadlines for the quarterly RAC meetings on the OBA website. Please familiarize yourself with Appendix M of the NIH Guidelines, which RAC uses to evaluate the appropriate biosafety practices and containment measures in a gene transfer study. Appendix M through Appendix M-I-B in particular is applicable at this stage of the process.
OBA has developed many tools to help you in your preparation of a submission to RAC, including a list of frequently asked questions on their website.
The investigator at MUSC should submit an IBC application throught MUSC electronic registrations system (ERMA). At minimum the uploads listed below need to be attached. It may not be possible to provide all uploads with the initial application, but if they are not available, they should be provided as soon as possible so as not to delay IBC processing.
- Appendix M as submitted to the NIH OBA Recombinant DNA Advisory Committee (RAC)
- Any correspondence sent by RAC to the submitting investigator regarding its review of the protocol
- Any correspondence sent by the submitting investigator to RAC in response to its review of the protocol
- The Clinical Trial Protocol
- The Investigators' Brochure for the clinical trial
- Informed Consent document submitted to the MUSC IRB
- Safety protocol covering the work described in the MUSC IBC application and specific to MUSC
- Biosafety training materials to be used with personnel at MUSC who may be exposed to the IBC registered agents
- Documentation from the Investigational Drug Services (IDS) Pharmacy regarding its role in handling the IBC registered agents
- "Cards" to be given to study participants and/or their caregivers with information relative to aftercare such as disposal of bandages or information for health care workers that the study participant may see
- Other information requested in, but not submitted on the IBC application form
In addition, please note that some uploads, in particular the safety protocol, will most likely undergo multiple revisions so that during the course of processing uploads will need to be replaced with the most current versions. Each version should be dated and numbered. It is most useful if changes in versions are indicated e.g. by highlighting them.
When preparing materials, applicable Medical Center, Pharmacy, and Infection Control Policies should be referred to. HRPP 4.11, Human Gene Transfer Studies Policy and Procedures, in the MUSC's IRB HRPP Program Guide should be consulted also. See Resources for links.
In addition, Dr. Daniel Eisenman, Biosafety Officer, (email@example.com, 792-4304) should be contacted as soon as possible for assistance with preparation of the safety protocol and the facilities inspection. The inspection which must be conducted of all areas in which the agents being registered are received, stored, processed, and administered and those in which the study participants will be until the time of discharge. Initial instructions on preparation of a safety protocol and the facilities inspection may be accessed at: www.musc.edu/biosafety/HGT/SOP .
See Appendix M-I-C of the NIH Guidelines for reporting requirements to NIH-OBA and MUSC IBC.
Reporting to the MUSC IBC:
At the time of Continuing Review, please submit:
- A copy of the latest annual report (See Appendix M-I-C-3) to NIH-OBA
- A copy of the cover letter that must accompany the submission of the annual report to NIH-OBA
- Any serious adverse events (See Appendix M-I-C-4) not already reported to the IBC.